How many Bevacizumab biosimilars are approved?

Drug Landscape tracks 0 approved Bevacizumab biosimilars across global regulators. 0 additional applications are filed and 0 are in Phase 3.

Is Bevacizumab still patent-protected?

All tracked patents on Bevacizumab have expired in tracked territories.

What is a biosimilar?

A biosimilar is a biological medicine highly similar to an already-approved reference biologic (the originator), with no clinically meaningful differences in safety, purity, or potency. Approved via abbreviated regulatory pathways once the originator's data exclusivity and patents expire.

Last reviewed 2026-05-14 · How we verify

Bevacizumab biosimilars

Complete Bevacizumab (Bevacizumab-Bvzr) biosimilar landscape: 0 approved biosimilars, 0 filed, 0 in Phase 3. Sponsor, approval status, first approval date, and patent timeline for the originator.

0 approved 0 filed 0 Phase 3 All key patents expired

About Bevacizumab

Bevacizumab (Bevacizumab-Bvzr) — originally marketed by Roche. Class: Monoclonal antibody. Target: Vascular Endothelial Growth Factor (VEGF). Area: Oncology. First approved 2004-01-01.

Approved biosimilars (0)

No approved biosimilars tracked for this originator.

Filed biosimilars under regulatory review (0)

No biosimilars currently under regulatory review.

Phase 3 biosimilars (0)

No biosimilars in Phase 3 clinical trials.

Originator patent timeline

Active patents (0)

No active patents tracked.

Expired patents (0)

No expired patents tracked.

Subscribe to biosimilar updates

Every regulatory action on Bevacizumab or any of its biosimilars:

Bevacizumab updates RSS
All Bevacizumab-Bvzr (originator + biosimilars) RSS

Bevacizumab full drug profile
Bevacizumab CI brief
All biosimilar landings